Amy Spoering, Director of Biological Research at the biotech NovoBiotic Pharmaceuticals, holds up a sample of the bacterium Eleftheria terrae, the basis for the promising new antibiotic Teixobactin, at NovoBiotic's labs in Cambridge, Massachusetts, U.S., November 22, 2016. To match Special Report USA-UNCOUNTED/DRUGS REUTERS/Brian Snyder